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Novel approaches to observational studies and clinical trials could improve the cost-effectiveness 
and speed of translation of research. Hybrid designs that combine elements of clinical trials with 
observational registries or cohort studies should be considered as part of a long-term strategy to 
transform clinical trials and epidemiology, adapting to the opportunities of big data and the 
challenges of constrained budgets. Important considerations include study aims, timing, breadth 
and depth of the existing infrastructure that can be leveraged, participant burden, likely 
participation rate and available sample size in the cohort, required sample size for the trial, and 
investigator expertise. Community engagement and stakeholder (including study participants) 
support are essential for these efforts to succeed.
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1. Introduction
The field of epidemiology has well-developed standards for the definition and conduct of 
many types of studies. This has resulted in a somewhat artificial dichotomy between clinical 
trials and observational studies in research, training and practice. Observational studies can 
include cohort studies and patient registries. Clinical trials may include randomized or non-
randomized efficacy or effectiveness trials of drugs, procedures or behavioral interventions. 
Trials could target individuals within a cohort with specific phenotypes or attributes. Trials 
to consider could include implementation or policy trials at individual (patient), clinic level, 
or community levels. Hybrid designs can include embedding clinical trials into existing 
observational studies or designing joint observational and trial components together in a 
single unified design.
In planning new studies, investigators should consider from the beginning a framework that 
includes the potential opportunities for concurrent or future intervention research or 
opportunities to extend clinical trials with an observational component. The factors that 
favor hybrid vs. separate study designs should be articulated and weighed. Optimal timing is 
important as it can become difficult to randomize once an intervention is introduced in the 
community. Ethical considerations including informed consent, medical referrals, and 
appropriateness of experimentation should be evaluated. It is also important to assess the 
appropriateness of specific cohorts for a particular clinical trial question as the inclusion and 
exclusion criteria, outcome assessments, and other logistic factors could differ. Investigators 
involved in existing cohorts and registries should thoroughly evaluate, on an ongoing basis, 
the potential types of interventions that could be incorporated. Registries should also be 
examined for opportunities to conduct trials as they are typically larger than population-
based cohort studies, more inclusive of “real world” patients, less expensive to assemble, 
and may be better for detecting safety signals. This report expands on an NIH workshop 
conducted to review these issues [1]. Specific examples from ongoing trials and 
observational studies are provided with recommendations for moving the field forward.
Newman et al. Page 2
Contemp Clin Trials. Author manuscript; available in PMC 2017 October 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Experience with combined cohort studies and clinical trials
Several studies have been conducted that have leveraged existing or concurrent cohorts in 
their design. The experience with these studies is provided with specific examples. Each 
illustrates a unique approach.
2.1. The strong heart and the stop atherosclerosis in native diabetics studies
The Stop Atherosclerosis in Native Diabetics (SANDS), [2] is an interventional trial 
embedded in the Strong Heart Study, The Strong Heart Study (SHS) is a prospective 
observational study of cardiovascular disease in 4549 tribal members ages 45–74 years in 
North and South Dakota, southwestern Oklahoma, and Arizona. In SHS, rates of coronary 
heart disease (CHD) were higher than rates in other US populations; most of the events 
occurred in individuals who had diabetes, that is, half of the population [3]. The SANDS 
Trial tested whether the reduction of LDL-C, non-HDL-C and tighter control of blood 
pressure would have a positive effect on CVD risk in American Indians with diabetes. Five 
hundred American Indians from SHS with diabetes but no prior CVD diagnoses were 
randomized into 2 treatment groups. The first group was treated to the currently 
recommended levels of lipids and blood pressure (LDL-C < 100 mg/dl, non-HDL-C < 130 
mg/dl and systolic BP < 130 mm/HG). The second group was treated to lower risk factor 
levels than were recommended at the time of the study (LDL-C < 70 mg/dl, non-HDL-C < 
100 mg/dl and systolic BP < 115 mm/HG). After 3 years of intervention, both groups 
demonstrated a reduction in atherosclerosis progression as measured by changes in carotid 
intima-medial thickness (CIMT), with the more aggressively treated group showing 
regression of CIMT [4]. The approach of embedding the trial in the cohort study was cost-
effective, as it used facilities and personnel already designated for the SHS study allowing 
completion in a more timely and economical fashion. In addition, it provided an important 
psychological boost to the large population of American Indians with diabetes who were 
witnessing a significant increase in CVD morbidity and mortality prior to the development 
of more aggressive risk factor management regimens.
2.2. The cardiovascular health study and the Ginkgo Evaluation of Memory Study
The Ginkgo Evaluation of Memory (GEM) Study was a double-blind, placebo controlled 
trial of Ginkgo biloba to reduce incidence of dementia. Secondary endpoints were 
cardiovascular diseases. There were 3072 participants aged 75+ in the four centers in the 
United States [5, 6]. The initial plan was to recruit participants from the Cardiovascular 
Health Study (CHS). Prior to the start of the trial, CHS participants were questioned as to 
willingness to participate and a high number were interested in the trial. However, of the 
2409 potential GEM participants from CHS, only 249 (10%) were recruited to the GEM 
Study. The 4 centers that participated in the CHS were very successful in using targeted 
mailing lists (243,400) to successfully recruit the additional GEM Study participants within 
the allotted time [7]. There were three important lessons: 1) it is difficult to recruit from a 
long-term, ongoing, longitudinal study after participants are no longer being evaluated in the 
clinic; 2) participant response to questionnaire about willingness to participate in a trial and 
actual participation may be discordant; and 3) large data bases available in experienced 
clinics provided a successful backup for recruitment, even for older participants.
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2.3. The Jackson Heart Study and the Health Promotion Study
African-Americans are recognized to carry an excess burden of cardiovascular disease 
(CVD) [8], and early results of the Jackson Heart Study (JHS) confirm high prevalence of 
traditional and putative risk factors for disease [9–11]. These facts stimulated intense interest 
among the JHS participants and JHS investigators in interventions that can impact outcome 
and alter the widening gap of mortality and morbidity between African-Americans and other 
groups. However, methodological concerns related to possible confounding of study 
observational outcomes have inhibited the “nesting” of clinical trials within the JHS cohort 
in the past. The Health Promotion Study is a pilot study testing the feasibility of a yoga 
intervention vs. regular walking and counseling among a cohort of middle-aged to elderly 
African Americans participating in the JHS, with a planned full-scale study to follow. The 
non-pharmacologic, non-invasive (and potentially homeopathic) nature of the intervention 
facilitated its approval by the JHS Steering Committee and the National Heart, Lung and 
Blood Institute (NHLBI), thus breaking the non-interventionalist history of the JHS. These 
same features are at least partly responsible for the rapid recruitment for the study. But 
perhaps the most important factors influencing participation in this trial were 1) the high 
level of trust of JHS and JHS-related activities among the cohort, along with 2) a high level 
of interest among cohort members in any novel efforts aimed at lowering their personal and 
familial risk of disease. Thus, of the 492 JHS participants prescreened (approximately 10% 
of the active JHS cohort) for eligibility, 438 were found to be eligible; only 6 participants 
refused to be prescreened. Of these, 382 participants have completed their baseline visit of 
whom 375 (86% of the eligible after prescreening) have been randomized. Study is 
underway to determine retention and adherence rates in each intervention arm: yoga (1, 2 or 
3 times per week); a walking-based exercise program; and a health education-only program. 
The results will provide insight into the feasibility of non-traditional approaches as possible 
adjuncts to usual care for persons at risk for CVD. The JHS study example was more 
successful than the CHS and we believe that the following were key factors: 1) the 
intervention was of interest to the study participants, 2) the cohort was still engaged in active 
follow-up and 3) the number of adverse health events had not yet begun to accumulate.
2.4. Embedding intensive behavioral therapy in a clinical setting
Intensive behavioral therapy (IBT) for obesity can be considered an intervention to embed in 
observational studies. Implementation studies can also be conducted in real life, clinical 
settings which serve as the cohorts from which the participants for intervention are drawn, 
thus embedding a trial within a practice. The Social and Health Research Center implements 
the BuenaVida intensive behavioral therapy (IBT) for obesity in South Alamo Medical 
Group primary care clinics in San Antonio, Texas using a pre–post evaluation design [12]. 
The Centers for Medicare and Medicaid Services (CMS) began reimbursing outpatient clinic 
for providing IBT for obesity in March, 2012. The Healthcare Common Procedure Coding 
System (HCPCS) code G0447, along with one of the ICD-10 for body mass index (BMI) 
30.0 and over (V85.30-V85.39), are used to bill for the service. The eligibility to participate 
is a BMI ≥30 kg/m2. The BuenaVida follows the programming schedule set by CMS: one 
15-min session every week during the first month; two sessions a month for the next two to 
six months; and one session a month for the next six months (18 sessions a year). A major 
problem with behavioral interventions is cost and sustainability. Because IBT for obesity is 
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now reimbursed by several health insurance plans ($24.21 a visit), sustainability might be 
facilitated. The evaluation of the intervention may better reflect effectiveness in a real world 
setting.
2.5. The Women’s Health Initiative Observational Study and Clinical Trial
The Women’s Health Initiative (WHI) is an example of a hybrid design from initiation [13]. 
The WHI involved 68,133 women recruited into one or more of the four clinical trials, 
consisting of two trials of post-menopausal hormone therapy, a trial of low-fat dietary 
modification, and a trial of calcium and vitamin D supplementation, as well as 93,676 
women who enrolled in the observational study. Participants were recruited from the 
communities surrounding the 40 WHI clinical centers. Eligibility for all components 
included age 50 to 79 years old, postmenopausal, and expected survival and local residency 
for at least 3 years. Women who were excluded from specific trials for reasons of safety, 
adherence or competing risk were offered enrollment in the observational study. Major 
outcomes in the trials included coronary heart disease, breast cancer, and hip fracture. The 
observational study goals were to explore the predictors and natural history of important 
health problems in postmenopausal women and to serve as a secular control for the clinical 
trials. Initial recruitment efforts were devoted to the dietary modification and hormone trials. 
For the observational study, there were two paths to enrollment with about half being 
accrued from each source: interested but ineligible for one of the trials or unwilling to be 
randomized and direct enrollment into the observational study. Women enrolled between 
1993 and 1998, and continue to be followed.
3. Pros and cons of hybrid observational and clinical trial design
There is a need for more rapid translation from observational studies to clinical trials. 
Intervention studies may be initiated in a more timely fashion if embedded in an existing 
study. This could foster more rapid testing and translation of new prevention and/or 
treatment strategies. The state of the science for individual study questions should set the 
timing for the introduction of interventions in observational studies vs. new studies. As 
observational studies demonstrate the importance of a risk factor for an outcome, more 
timely translation to intervention studies is needed. The significance of the research question 
and the potential impact of the question on the health/disease status of the observational 
study population should determine whether the intervention study would be best conducted 
within that observational (cohort) study. In cases where the cohort has been followed for a 
long time and health outcomes have already occurred, a new hybrid design (clinical trial 
with cohort component) with recruitment of a new study population may be needed.
Timing is critical. Testing interventions related to a new risk factor or involving a new 
technology should be done early enough before the treatment or new technology of interest 
are widely adopted. Once new treatments or technologies are widely utilized in the 
community, especially when paid for by third party payers, insurance companies, etc., the 
ability to do trials is greatly limited because of the substantial “crossovers” within the trial, 
i.e., individuals obtaining diagnostic techniques or therapies from other sources than the 
trial. Timing considerations also are relevant to observational studies; once studies are 
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established, participants may be less willing to be part of a new study that requires more 
visits or procedures. The experience with recruiting from the CHS study for the GEM trial is 
one example of this. There might be trade-offs between the needs of the intervention study 
and the observational study. For example, it might not be possible for the observational study 
to have enough power for its aims if the intervention substantially alters the natural history 
of the condition. In this situation, the intervention study needs to be important enough for 
embedding to be allowed to occur. Should a clinical trial be added, the investigators should 
monitor its impact on the outcomes and adverse events of the observational study.
Embedding an intervention study in a cohort study can enhance external generalizability and 
calibration of risk estimates. Randomized clinical trials (RCTs) are designed to address very 
specific hypotheses; a single intervention tested in a well-defined study population to 
provide definitive results for one primary outcome or at most a small number of designated 
outcomes. Even when the trial results are crystal clear, a large number of questions often 
arise: Do these results apply to other related interventions (similar drugs, related screening 
strategies, alternative behavioral interventions) or can we determine the critical component 
of an intervention that is driving the findings (specific aspects of diet or of exercise patterns, 
weight loss or cardiopulmonary fitness)? Do trial results generalize to populations that were 
excluded from the trial, perhaps for access, feasibility, cost or other factors that are difficult 
to manage within the trial itself (e.g., those with co-morbidities)? Are there other important 
outcomes, beyond those targeted in the trial, that are affected by the intervention for which 
the trial itself was not powered to detect? When trial results contradict prior observational 
studies or practice, questions of generalizability become even more prominent.
Our research enterprise does not have the wherewithal to mount additional trials to answer 
even the most important questions raised in this context. Further, in some instances the 
ethics of doing so would be questionable. But these are important questions that can be 
anticipated and in some instances addressed in a cost-efficient manner by embedding a RCT 
in a broader observational study or registry. If the intervention or related interventions are 
already in use in the general population, a resource that amasses the data in this 
observational setting in a parallel fashion could be used to extend the results of the clinical 
trial.
Such an approach has been used to considerable advantage in the WHI to elucidate the 
effects of hormone therapy on chronic disease risk. In a series of articles, Prentice and 
colleagues, [14–19] jointly analyzed data from the two WHI hormone trials and the parallel 
WHI observational study, demonstrating that only a small fraction of the discrepancies 
between prior observational studies and the RCTs was explained by traditional confounding. 
The more important source of these differences arose from the time-dependent effects of 
hormone therapy, often missed in observational studies, and the timing of initiation of 
hormone use relative to menopause (gap time). Similar joint analyses improved the power to 
examine subgroup analyses of the hormone trials and the WHI Calcium and Vitamin D trials 
[20] and to analyze other endpoints for which the trials were not adequately powered. 
Fundamental to these analyses was the comparability of the underlying study population 
(recruited simultaneously from the same communities) and the data collection in both study 
components, limiting methodological disparities [21].
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It is important to note that there are great efficiencies that can be realized from hybrid 
designs. Potential advantages accrue from pre-existing, well-characterized, and engaged 
populations that are already under active follow-up. Very simple interventions such as 
randomizing the reporting of screening and follow-up should be considered. Pre-existing 
procedures for case finding, retention, outcome ascertainment and event classification enable 
rapid trial initiation and obviate the need to separately establish (and fund) infrastructure for 
trial-related procedures.
Randomized drug/comparative effectiveness research/safety trials should be of sufficient 
impact and quality to contribute to evidence-base for public health and clinical practice 
guidelines. The availability of data with limitations in quantity or quality should not 
preclude proposing and designing well powered, definitive studies. Researchers should 
recognize that some cohort studies may not offer sufficient sample size, particularly if effect 
sizes are small and/or there are multiple inclusion/exclusion criteria. Additionally, it is 
important to recognize that cohort studies also have exclusions and selection bias that must 
be considered in determining generalizability of a hybrid design.
To determine the benefits and risks of adding a clinical trial component to an observational 
study, clinical trials experts need to be included on the team. Clinical trials experts can work 
with observational studies researchers to optimize trial design, infrastructure needs, 
statistical issues, screening and recruitment, informed consent, adverse-event reporting, 
event definitions and adjudication, and strategies on retention and adherence. Conversely, 
observational studies researchers can help clinical trialists achieve efficiencies by drawing 
on their own staff, infrastructure, follow-up, case finding, and event classifications 
procedures.
4. Examples of hybrid designs based on registries and comparative 
effectiveness
Randomized clinical trials suffer from uncertainty about generalizability to broader 
populations, expense and limited power, especially in subgroups. Randomized trials may 
also not address questions of societal interest. Thus, non-randomized approaches using data 
from observational databases can be used to address questions of clinical interest. However, 
the problem with comparing therapeutic or diagnostic strategies with observational data is 
residual treatment selection bias due to unmeasured confounders, measurement error or bias 
in surveillance. An area of continuing interest is the choice of revascularization strategy for 
stable ischemic heart disease. In particular, questions remain concerning the comparative 
effectiveness of percutaneous coronary intervention (PCI) and coronary-artery bypass 
grafting (CABG).
The American College of Cardiology Foundation (ACCF) and the Society of Thoracic 
Surgeons (STS) have developed a partnership, the ACCF and STS Database Collaboration 
on the Comparative Effectiveness of Revascularization Strategies (ASCERT), to compare the 
outcomes of PCI and CABG, using information from records in their respective societal 
databases, with follow-up data from claims records of the CMS. In ASCERT, the ACCF 
National Cardiovascular Data Registry and the STS Adult Cardiac Surgery Database were 
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linked to claims data from the CMS for the years 2004 through 2008. Outcomes were 
compared with the use of propensity scores and inverse-probability-weighting adjustment to 
reduce treatment selection bias. Among patients 65 years of age or older who had two-vessel 
or three-vessel coronary artery disease without acute myocardial infarction, there was no 
significant difference in adjusted mortality between the groups (6.24% in the CABG group 
as compared with 6.55% in the PCI group; risk ratio, 0.95; 95% confidence interval [CI], 
0.90 to 1.00) at one year. At 4 years, there was lower mortality with CABG than with PCI 
(16.4% vs. 20.8%; risk ratio, 0.79; 95% CI, 0.76 to 0.82) [22]. The possible influence of 
residual confounding was assessed by means of a sensitivity analysis. In this observational 
study, we found that among older patients with multivessel coronary disease that did not 
require emergency treatment, there was a long-term survival advantage among patients who 
underwent CABG as compared with patients who underwent PCI. These data are largely 
consistent with clinical trials though they do not address medical therapy which is also 
effective [23]. Thus, comparative effectiveness studies using data from large registries can be 
used to address issues of societal interest, but the problem of treatment selection bias 
remains.
Large national registries have been developed to evaluate specific disease outcomes but also 
the processes and infrastructure of patient care. Observational data from registries can 
extend the value of clinical trials because they are more inclusive of real-world patients and 
can include very large cohorts at less expense. Observational data from registries can be 
hypothesis generating and help detect safety signals for rare events. For example, fatal stent 
thrombosis is rare but detectable through registry follow-up [24]. Registry infrastructure 
offers multiple operational efficiencies to both study coordination and to sites participating 
in RCTs. The study of access sites for enhancing PCI in women showed a 65% reduction in 
workload for site coordinators using an ongoing registry for recruitment [25]. Alignment of 
objectives and operational structure with federal public health, regulatory and 
reimbursement science promotes a collaborative and inclusive and cost effective approach 
for all stakeholders interested in uncovering new device indications and best practice 
guidelines.
5. Pros and cons of registries
Registries offer researchers large populations of well-characterized patients with a wide 
variety of diseases, conditions, and interactions with clinical care. Researchers should 
consider linking clinical registry databases with administrative databases, in particular for 
enabling efficient recruitment, screening, and follow-up. Limitations of registries may 
include lack of a biorepository, disease-specificity that may render them less valuable for 
primary prevention trials, potential need for additional data collection of data outside the 
administrative data or medical record (such as quality of life, adverse events, or adherence), 
the lower quality and completeness of administrative data and challenging requirements for 
statistical methodologies.
Observational registry studies were not designed to test the efficacy or even effectiveness of 
specific therapies or technologies, but have their primary value in monitoring quality and 
quantity of outcomes and signals for unexpected adverse or even potentially beneficial 
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effects, especially within specific disease subgroups defined on genetics, demographics, or 
health-related characteristics in non-randomized comparative effectiveness studies. In this 
way, registries can assess the consistency of the findings of clinical trials in populations not 
represented in a RCT. While registry studies can be large, size does not overcome treatment 
selection bias. Specific methods must be used to limit such biases. These include restriction 
to indication, application of inclusion and exclusion criteria at “time zero” and using an 
intention-to-treat approach [26].
6. Need for partnerships
Observational studies have often gained broad community engagement to support the need 
for long term follow-up. If an intervention is considered for an observational study, 
researchers should strongly consider engaging pertinent stakeholders, including the study 
participants and their communities, in the formulation of the research questions, the 
oversight, and implementation of the intervention study. Diversity and inclusiveness are 
important principles. Many of the populations in need of new approaches to care may be 
more difficult to reach, but should be included in efforts to conduct both observational and 
clinical trial research.
Both epidemiological and clinical studies that intend to generate findings and interventions 
that would generalizable to a large proportion of the population require adequate 
representation of those most at-risk of disease and susceptible to disparities. The recruitment 
of minority and underserved individuals into research studies is often perceived as 
challenging or problematic by many, [27] whereas others have found that individuals from 
these groups are more open to participating in research that often thought [28].
The spectrum of challenges that may be encountered during recruitment and follow-up of 
participants from underserved communities ranges from staff issues (for example, number 
and qualifications), [20] administrative issues (for example, identifying appropriate space 
where studies could be performed, complying with all regulations), [20] target population 
issues (inclusion and exclusion criteria; research question not resonant with the target 
population’s culture and perceived needs; high no show rate to appointments; individual’s 
distrust of the research and medical system) [29] and investigator’s own issues (for example, 
beliefs and perceptions about the target population and the scientific relevance of the 
question of interest) [30].
Strategies to overcome potential challenges may include hiring of staff who are familiar with 
or proficient on the target population’s culture and able to communicate in the same 
language; [31,32] recruiting participants from clinical settings; [32] inviting physicians to 
refer participants; [27,33] reaching out to community partners and involving community key 
stakeholders in the identification of the relevant research questions, design of the recruitment 
and follow-up plan; [34,35] communicate clearly and with veracity; [31] and one of the most 
fundamental strategies is to formulate a research question and study design that are relevant 
to the target population [33].
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7. Summary of recommendations
Based on the considerations discussed above, the authors agree that established 
observational registries and cohort studies offer an infrastructure essential for embedding 
clinical trials, and specific opportunities for the implementation of this hybrid model should 
be developed. Building on the existing infrastructure would foster more rapid translation of 
findings from observational studies or registries into clinical applications. At the same time, 
the significance, impact and timing of the research question will determine whether the 
intervention should be implemented in an established observational study. Ethical aspects, 
such as obtaining consent to participate in the trial, appropriateness of the intervention in the 
study population, adverse events and medical referrals need to be considered. Finally, 
resonance of the research question with the population or community of interest and 
partnership with stakeholders (i.e. researchers, health care providers, community leaders, 
funding agencies, health policy and insurance experts) are fundamental for the success of the 
implementation of this model.
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